Viridian Therapeutics, Inc.\DE

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

VRDN$30.86+2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share data)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B
Shares · Amount · Shares · Amount · Shares · Amount
Balance as of December 31, 2022	188,381		$85,470		51,210			$56,677			41,305,947		$414			$741,067			$(390)			$(488,174)			$395,064
Issuance of common stock upon conversion of convertible preferred stock	(15,946)		(7,235)		—			—			1,063,118		10			7,225			—			—			—
Issuance of common stock under license agreement	—	—		—			—			243,902			3			5,690			—			—			5,693
Issuance of Series B convertible preferred stock and common stock in private placement offering, net of issuance costs of $4,588 and $6,805, respectively	—	—		92,312		71,604			8,869,797			89			102,914			—			—			174,607
Issuance of common stock in at-the-market offerings, net of issuance costs of $493	—	—		—			—			684,298		7			14,761		—			—			14,768
Issuance of common stock upon exercises of warrants	—	—		—			—			114,219		1			1,880			—			—			1,881
Issuance of common stock upon exercises of stock options	—	—		—			—			1,538,199		15			19,248			—			—			19,263
Issuance of common stock under employee stock purchase plan	—	—		—			—			31,216		—			580			—			—			580
Issuance of common stock upon vesting of restricted stock units	—	—		—			—			135,416		1			(1)			—			—			—
Share-based compensation expense	—	—		—			—			—		—			67,172			—			—			67,172
Unrealized gain on available-for-sale securities	—	—		—			—			—		—			—			728			—			728
Net loss	—	—		—			—			—		—			—			—			(237,734)			(237,734)
Balance as of December 31, 2023	172,435	$78,235		143,522			$128,281			53,986,112		$540			$960,536			$338			$(725,908)			$442,022
Issuance of common stock upon conversion of convertible preferred stock	(37,571)		(17,047)		(18,362)			(24,085)			3,729,048		37			41,095			—			—			—
Issuance of common stock in January 2024 underwritten offering, net of issuance costs of $9,304	—	—		—		—			7,142,858		71			140,625			—			—			140,696
Issuance of Series B convertible preferred stock and common stock in September 2024 underwritten offering, net of issuance costs of $1,500 and $13,954, respectively	—	—		20,000		23,501			12,466,600			125			219,669			—			—			243,295
Issuance of common stock in at-the-market offerings, net of issuance costs of $2,156	—	—		—			—			3,058,751			31			67,724			—			—			67,755
Issuance of common stock upon exercises of stock options	—	—		—		—			437,146		4			5,340			—			—			5,344
Issuance of common stock under employee stock purchase plan	—	—		—		—			44,136		1			673			—			—			674
Issuance of common stock upon vesting of restricted stock units	—	—		—			—			129,395			1			(1)			—			—			—
Share-based compensation expense	—	—		—		—			—		—			42,150			—			—			42,150
Unrealized loss on available-for-sale securities	—	—		—		—			—		—			—			(348)			—			(348)

Convertible Preferred Stock · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Series A · Series B · Common Stock · AdditionalPaid-inCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity
	Shares	Amount	Shares	Amount	Shares	Amount	AdditionalPaid-inCapital	Accumulated Other Comprehensive Income (Loss)	AccumulatedDeficit	TotalStockholders’Equity
Net loss	—	—	—	—	—	—	—	—	(269,949)	(269,949)
Balance as of December 31, 2024	134,864	$61,188	145,160	$127,697	80,994,046	$810	$1,477,811	$(10)	$(995,857)	$671,639
Issuance of common stock upon conversion of convertible preferred stock	—	—	(65,540)	(56,829)	4,369,551	44	56,785	—	—	—
Issuance of common stock in an underwritten offering, net of issuance costs of $17,280	—	—	—	—	13,138,750	131	271,626	—	—	271,757
Issuance of common stock in at-the-market offerings, net of issuance costs of $1,323	—	—	—	—	2,216,864	22	61,800	—	—	61,822
Issuance of common stock upon exercises of warrants	—	—	—	—	115,146	1	1,617	—	—	1,618
Issuance of common stock upon exercises of stock options	—	—	—	—	811,970	8	12,045	—	—	12,053
Issuance of common stock under employee stock purchase plan	—	—	—	—	84,556	1	1,118	—	—	1,119
Issuance of common stock upon vesting of restricted stock units	—	—	—	—	95,617	1	(1)	—	—	—
Share-based compensation expense	—	—	—	—	—	—	44,303	—	—	44,303
Unrealized gain on available-for-sale securities	—	—	—	—	—	—	—	457	—	457
Net loss	—	—	—	—	—	—	—	—	(342,601)	(342,601)
Balance as of December 31, 2025	134,864	$61,188	79,620	$70,868	101,826,500	$1,018	$1,927,104	$447	$(1,338,458)	$722,167

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.